The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Somatic Mutations in the MTOR gene cause focal cortical dysplasia type II b
Abstract
Objective: Focal cortical dysplasia (FCD) type IIb is a cortical malformation characterized by cortical architectural abnormalities, dysmorphic neurons, and balloon cells. It has been suggested that FCDs are caused by somatic mutations in cells in the developing brain. Here, we explore the possible involvement of somatic mutations in FCD type IIb. Methods: We collected a total of 24 blood‐brain paired samples with FCD, including 13 individuals with FCD type IIb, 5 with type IIa, and 6 with type I. We performed whole‐exome sequencing using paired samples from 9 of the FCD type IIb subjects. Somatic MTOR mutations were identified and further investigated using all 24 paired samples by deep sequencing of the entire gene's coding region. Somatic MTOR mutations were confirmed by droplet digital polymerase chain reaction. The effect of MTOR mutations on mammalian target of rapamycin (mTOR) kinase signaling was evaluated by immunohistochemistry and Western blotting analyses of brain samples and by in vitro transfection experiments. Results: We identified four lesion‐specific somatic MTOR mutations in 6 of 13 (46%) individuals with FCD type IIb showing mutant allele rates of 1.11% to 9.31%. Functional analyses showed that phosphorylation of ribosomal protein S6 in FCD type IIb brain tissues with MTOR mutations was clearly elevated, compared to control samples. Transfection of any of the four MTOR mutants into HEK293T cells led to elevated phosphorylation of 4EBP, the direct target of mTOR kinase. Interpretation: We found low‐prevalence somatic mutations in MTOR in FCD type IIb, indicating that activating somatic mutations in MTOR cause FCD type IIb. Ann Neurol 2015;78:375–386
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“Allele counting was performed using Integrative Genomics Viewer software (IGV).(25)”
MethodA map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 2×
“mTORC2 is composed of mTOR, mLST8, Rictor, and mSin1 and phosphorylates Akt, PKC, and SGK, which are involved in cell cycle, cell survival, and actin organization and morphology.(32,40,41) Rapamycin, an allosteric inhibitor of mTOR, binds to mTOR with FKBP12 and inhibits kinase activity of mTORC1.”
BackgroundLoewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Guerois, R., Nielsen, J. E., & Serrano, L. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00442-4 · Cited by 1,728 · cited 1×
“0b3) was used to calculate free energy changes after mutation using the mTOR crystal structure (amino acids [aa] 1,376–2,549)/mLST8 complex (Protein Data Bank [PDB] 4JSN).(27) The calculation was repeated three times, and the resultant data are presented as an average value with a standard deviation.”
MethodBar-Peled, L., Chantranupong, L., Cherniack, A. D., Chen, W. W., Ottina, K. A., Grabiner, B. C., Spear, E. D., Carter, S. L., Meyerson, M., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1232044 · Cited by 1,080 · cited 1×
“Gator1 has GTPaseactivating activity for RagA/B and thus suppresses mTORC1 activity in static and low-amino-acid conditions.(39) Therefore, loss of function in PTEN and Gator1 may cause mTOR activation.”
BackgroundmTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075 · cited 2×
“To evaluate the effects of missense mutations on mTOR function from a structural viewpoint, we mapped their location on the mTOR crystal structure (aa 1,376–2,549) in complex with mLST8, ATPcS, and magnesium ions.(31) The FRB domain in the N-lobe and helix 9b in the C-lobe hinder substrate access to the active site, n…”
BackgroundFinding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741
Somatic mutation, genomic variation, and neurological disease
Poduri, A., Evrony, G. D., Cai, X., & Walsh, C. A. (2013) · Science · doi:10.1126/science.1237758 · Cited by 584
Takei, N., Inamura, N., Kawamura, M., Namba, H., Hara, K., Yonezawa, K., & Nawa, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1427-04.2004 · Cited by 442 · cited 1×
“Immunoprecipitates were analyzed by SDS-PAGE and Western blotting with anti-phospho-4EBP (Thr37/46; Cell Signaling Technologies) or anti-DYKDDDDK (WAKO), as previously described.(30) Results”
MethodSelf-citationJansen, L. A., Mirzaa, G. M., Ishak, G. E., O'Roak, B. J., Hiatt, J. B., Roden, W. H., Gunter, S. A., Christian, S. L., Collins, S., Adams, C., et al. (2015) · Brain · doi:10.1093/brain/awv045 · Cited by 364 · cited 1×
“These findings supported the hypothesis that MTOR-mutation–negative subjects may have mutations in other molecular members of the pathway, which lead to net activation of the mTOR signaling.(19) We also investigated MTOR mutations in limited numbers of brain samples with FCD type I and IIa (six in type I and five in t…”
ResultmTOR signaling and its roles in normal and abnormal brain development
Takei, N., & Nawa, H. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00028 · Cited by 317 · cited 3×
“Somatic MTOR mutations in FCD type IIb are likely to cause hyperactivation of the mTOR-signaling pathway, which is involved in growth, migration, and the maturation of neurons and glial cells.(8) All individuals with MTOR mutations showed distinctive balloon cells in their brain tissues (Fig 3 C, F, I, L, O, R).”
BackgroundSelf-citationmTOR: A pathogenic signaling pathway in developmental brain malformations
Crino, P. B. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.07.008 · Cited by 266
Pathogenetic mechanisms of focal cortical dysplasia
Marin‐Valencia, I., Guerrini, R., & Gleeson, J. G. (2014) · Epilepsia · doi:10.1111/epi.12650 · Cited by 100
Cited by
Lim, J. S., Kim, W.-I., Kang, H.-C., Kim, S. H., Park, A. H., Park, E. K., Cho, Y.-W., Kim, S., Kim, H. M., Kim, J. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3824 · Cited by 518
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Molecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz-Kaminska, A., Zmorzynska, J., & Jaworski, J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 387
The mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368
Najm, I., Lal, D., Alonso Vanegas, M., Cendes, F., Lopes‐Cendes, I., Palmini, A., Paglioli, E., Sarnat, H. B., Walsh, C. A., Wiebe, S., et al. (2022) · Epilepsia · doi:10.1111/epi.17301 · Cited by 361
Metadata
- Authors
- Nakashima, M., Saitsu, H., Takei, N., Tohyama, J., Kato, M., Kitaura, H., Shiina, M., Shirozu, H., Masuda, H., Watanabe, K., Ohba, C., Tsurusaki, Y., Miyake, N., Zheng, Y., Sato, T., Takebayashi, H., Ogata, K., Kameyama, S., Kakita, A., & Matsumoto, N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2015-07-03
- Volume
- 78
- Issue
- 3
- Pages
- 375-386
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1483653355
- Cited by
- 196
- References
- 15
- FWCI
- 19.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.